Seok-Yong Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9174105/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Korean Red Ginseng inhibits methamphetamine addictive behaviors by regulating dopaminergic and NMDAergic system in rodents. Journal of Ginseng Research, 2022, 46, 147-155.	5.7	3
2	Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects. Archives of Pharmacal Research, 2022, 45, 114-121.	6.3	12
3	Repeated Morphine Administration Increases <i>TRPV1</i> mRNA Expression and Autoradiographic Binding at Supraspinal Sites in the Pain Pathway. Biomolecules and Therapeutics, 2022, 30, 328-333.	2.4	3
4	Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism. Archives of Pharmacal Research, 2022, 45, 352-366.	6.3	12
5	Mepirapim, a Novel Synthetic Cannabinoid, Induces Addiction-Related Behaviors through Neurochemical Maladaptation in the Brain of Rodents. Pharmaceuticals, 2022, 15, 710.	3.8	3
6	Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes. Archives of Pharmacal Research, 2022, 45, 433-445.	6.3	8
7	Korean Red Ginseng reduces chronic social defeat stress-induced mood disorders via N-methyl-D-aspartateÂreceptor modulation in mice. Journal of Ginseng Research, 2021, 45, 254-263.	5.7	7
8	Antineuroinflammatory Effects of 7,3',4'-Trihydroxyisoflavone in Lipopolysaccharide-Stimulated BV2 Microglial Cells through MAPK and NF-κB Signaling Suppression. Biomolecules and Therapeutics, 2021, 29, 127-134.	2.4	10
9	Abuse Potential of Synthetic Cannabinoids: AM-1248, CB-13, and PB-22. Biomolecules and Therapeutics, 2021, 29, 384-391.	2.4	4
10	Methoxphenidine (MXP) induced abnormalities: Addictive and schizophreniaâ€related behaviours based on an imbalance of neurochemicals in the brain. British Journal of Pharmacology, 2021, 178, 3869-3887.	5.4	5
11	Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. Archives of Pharmacal Research, 2021, 44, 713-724.	6.3	23
12	New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents. Archives of Toxicology, 2021, 95, 1413-1429.	4.2	6
13	Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Archives of Pharmacal Research, 2021, 44, 1037-1049.	6.3	12
14	Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Archives of Pharmacal Research, 2021, 44, 1109-1119.	6.3	13
15	Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes. Archives of Pharmacal Research, 2021, 44, 1076-1090.	6.3	16
16	Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects. Archives of Pharmacal Research, 2020, 43, 976-981.	6.3	11
17	Flavonoids as therapeutic candidates for emotional disorders such as anxiety and depression. Archives of Pharmacal Research, 2020, 43, 1128-1143.	6.3	35
18	Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes. Archives of Pharmacal Research, 2020, 43, 1356-1363.	6.3	14

#	Article	IF	CITATIONS
19	Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Archives of Pharmacal Research, 2020, 43, 1207-1213.	6.3	24
20	ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan. Archives of Pharmacal Research, 2020, 43, 1187-1196.	6.3	19
21	Protective effect of EX-527 against high-fat diet-induced diabetic nephropathy in Zucker rats. Toxicology and Applied Pharmacology, 2020, 390, 114899.	2.8	18
22	Memory-enhancing effects of 7,3′,4′-trihydroxyisoflavone by regulation of cholinergic function and BDNF signaling pathway in mice. Food and Chemical Toxicology, 2020, 137, 111160.	3.6	11
23	25C-NBF, a new psychoactive substance, has addictive and neurotoxic potential in rodents. Archives of Toxicology, 2020, 94, 2505-2516.	4.2	15
24	Transient receptor potential vanilloid 1 mediates cocaine reinstatement via the D1 dopamine receptor in the nucleus accumbens. Journal of Psychopharmacology, 2019, 33, 1491-1500.	4.0	7
25	Effect of icatibant on angiotensinâ€converting enzyme inhibitorâ€induced angioedema: A metaâ€analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 685-692.	1.5	23
26	lsoorientin improves scopolamine-induced cognitive impairments by restoring the cholinergic system, antioxidant defense, and p-CREB/BDNF signaling in the hippocampus and frontal cortex. Archives of Pharmacal Research, 2019, 42, 722-731.	6.3	19
27	A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents. Brain Research Bulletin, 2019, 152, 19-26.	3.0	22
28	Protective effects of 6,7,4′-trihydroxyisoflavone, a major metabolite of daidzein, on 6-hydroxydopamine-induced neuronal cell death in SH-SY5Y human neuroblastoma cells. Archives of Pharmacal Research, 2019, 42, 1081-1091.	6.3	8
29	Lespedeza bicolor Extract Improves Amyloid Beta25 – 35-Induced Memory Impairments by Upregulating BDNF and Activating Akt, ERK, and CREB Signaling in Mice. Planta Medica, 2019, 85, 1363-1373.	1.3	13
30	7,8,4'-Trihydroxyisoflavone, a Metabolized Product of Daidzein, Attenuates 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells. Biomolecules and Therapeutics, 2019, 27, 363-372.	2.4	15
31	<i>Dendropanax morbifera</i> Ameliorates Thioacetamide-Induced Hepatic Fibrosis via TGF-β1/Smads Pathways. International Journal of Biological Sciences, 2019, 15, 800-811.	6.4	35
32	Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects. Archives of Pharmacal Research, 2019, 42, 1101-1106.	6.3	14
33	Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine. Archives of Pharmacal Research, 2019, 42, 182-190.	6.3	21
34	6,7,4′-Trihydroxyisoflavone, a major metabolite of daidzein, improves learning and memory via the cholinergic system and the p-CREB/BDNF signaling pathway in mice. European Journal of Pharmacology, 2018, 826, 140-147.	3.5	30
35	Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites. Archives of Pharmacal Research, 2018, 41, 347-353.	6.3	20
36	Blockade of TRPV1 Inhibits Methamphetamine-induced Rewarding Effects. Scientific Reports, 2018, 8, 882.	3.3	13

#	Article	IF	CITATIONS
37	Repeated restraint stress reduces the acquisition and relapse of methamphetamine-conditioned place preference but not behavioral sensitization. Brain Research Bulletin, 2018, 139, 99-104.	3.0	6
38	Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes. Archives of Pharmacal Research, 2018, 41, 564-570.	6.3	10
39	The new designer drug buphedrone produces rewarding properties via dopamine D1 receptor activation. Addiction Biology, 2018, 23, 69-79.	2.6	13
40	The role of striatal Gα q/11 protein in methamphetamine-induced behavioral sensitization in mice. Behavioural Brain Research, 2018, 346, 66-72.	2.2	3
41	TRPV1 modulates morphine self-administration via activation of the CaMKII-CREB pathway in the nucleus accumbens. Neurochemistry International, 2018, 121, 1-7.	3.8	10
42	Novel SIRT1 inhibitor 15-deoxy-Δ12,14-prostaglandin J2 and its derivatives exhibit anticancer activity through apoptotic or autophagic cell death pathways in SKOV3 cells. International Journal of Oncology, 2018, 53, 2518-2530.	3.3	21
43	The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. Archives of Pharmacal Research, 2018, 41, 931-936.	6.3	11
44	The change of signaling pathway on the electrical stimulated contraction in streptozotocin-induced bladder dysfunction of rats. Korean Journal of Physiology and Pharmacology, 2018, 22, 577.	1.2	4
45	CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Archives of Pharmacal Research, 2018, 41, 921-930.	6.3	37
46	Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites. European Journal of Clinical Pharmacology, 2018, 74, 1417-1426.	1.9	16
47	The memory-enhancing effects of 7,8,4'-trihydroxyisoflavone, a major metabolite of daidzein, are associated with activation of the cholinergic system and BDNF signaling pathway in mice. Brain Research Bulletin, 2018, 142, 197-206.	3.0	21
48	Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem. Archives of Pharmacal Research, 2018, 41, 861-866.	6.3	9
49	Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review. Therapeutics and Clinical Risk Management, 2018, Volume 14, 83-93.	2.0	9
50	Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes. Scientific Reports, 2018, 8, 12405.	3.3	19
51	The Memory-Enhancing Effects of Liquiritigenin by Activation of NMDA Receptors and the CREB Signaling Pathway in Mice. Biomolecules and Therapeutics, 2018, 26, 109-114.	2.4	18
52	Evodiamine Reduces Caffeine-Induced Sleep Disturbances and Excitation in Mice. Biomolecules and Therapeutics, 2018, 26, 432-438.	2.4	18
53	Physiologically based pharmacokinetic modelling of atomoxetine in the different CYP2D6 genotypes. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-14-2.	0.0	0
54	Repeated restraint stress reduces the acquisition and relapse of methamphetamine-conditioned place preference but not behavioral sensitization. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-83.	0.0	0

#	Article	IF	CITATIONS
55	Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes. FASEB Journal, 2018, 32, lb656.	0.5	0
56	The new stimulant designer compound pentedrone exhibits rewarding properties and affects dopaminergic activity. Addiction Biology, 2017, 22, 117-128.	2.6	15
57	The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics, 2017, 18, 459-469.	1.3	25
58	Liquiritigenin ameliorates memory and cognitive impairment through cholinergic and BDNF pathways in the mouse hippocampus. Archives of Pharmacal Research, 2017, 40, 1209-1217.	6.3	37
59	TRPV1 modulates morphine-induced conditioned place preference via p38 MAPK in the nucleus accumbens. Behavioural Brain Research, 2017, 334, 26-33.	2.2	27
60	Bioequivalence Study of a New Fixed-dose Combination Tablet Containing S-Amlodipine Nicotinate and Olmesartan Medoxomil in Healthy Korean Male Subjects. Clinical Therapeutics, 2017, 39, 1371-1379.	2.5	5
61	Simple and rapid determination of zaltoprofen in human plasma by manualâ€shakingâ€assisted dispersive liquid–liquid microextraction followed by liquid chromatography with ultraviolet detection. Journal of Separation Science, 2017, 40, 4050-4059.	2.5	4
62	Inhibition of salivary secretion by tolterodine transdermal patch. Archives of Pharmacal Research, 2017, 40, 1455-1463.	6.3	2
63	Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC–MS/MS and its application to a pharmacokinetic study. Archives of Pharmacal Research, 2017, 40, 1287-1295.	6.3	4
64	Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Archives of Pharmacal Research, 2017, 40, 382-390.	6.3	39
65	Impairment of opiateâ€mediated behaviors by the selective TRPV1 antagonist SB366791. Addiction Biology, 2017, 22, 1817-1828.	2.6	17
66	The Anti-Inflammatory Activity of Eucommia ulmoides Oliv. Bark. Involves NF-κB Suppression and Nrf2-Dependent HO-1 Induction in BV-2 Microglial Cells. Biomolecules and Therapeutics, 2016, 24, 268-282.	2.4	32
67	Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast. Archives of Pharmacal Research, 2016, 39, 1013-1019.	6.3	14
68	Phentermine induces conditioned rewarding effects via activation of the PI3K/Akt signaling pathway in the nucleus accumbens. Psychopharmacology, 2016, 233, 1405-1413.	3.1	7
69	Mild and Site-Selective Allylation of Enol Carbamates with Allylic Carbonates under Rhodium Catalysis. Journal of Organic Chemistry, 2016, 81, 2243-2251.	3.2	38
70	New ethanol extraction improves the anti-obesity effects of black tea. Archives of Pharmacal Research, 2016, 39, 310-320.	6.3	20
71	Quinpirole Increases Melatonin-Augmented Pentobarbital Sleep via Cortical ERK, p38 MAPK, and PKC in Mice. Biomolecules and Therapeutics, 2016, 24, 115-122.	2.4	11
72	<i>Vaccinium bracteatum</i> Thunb. Exerts Anti-Inflammatory Activity by Inhibiting NF-κB Activation in BV-2 Microglial Cells. Biomolecules and Therapeutics, 2016, 24, 543-551.	2.4	29

#	Article	IF	CITATIONS
73	Rh(III)-Catalyzed Direct Coupling of Azobenzenes with α-Diazo Esters: Facile Synthesis of Cinnolin-3(2 <i>H</i>)-ones. Organic Letters, 2015, 17, 2852-2855.	4.6	108
74	Determination of zolpidem in human plasma by liquid chromatography–tandem mass spectrometry for clinical application. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 986-987, 129-134.	2.3	13
75	Rh(III)-Catalyzed C–H Amidation of Indoles with Isocyanates. Journal of Organic Chemistry, 2015, 80, 7243-7250.	3.2	42
76	Synthesis of N-Sulfonylamidated and Amidated Azobenzenes under Rhodium Catalysis. Journal of Organic Chemistry, 2015, 80, 8026-8035.	3.2	32
77	Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. Archives of Pharmacal Research, 2015, 38, 1232-1237.	6.3	17
78	3′,4′,7-Trihydroxyflavone prevents apoptotic cell death in neuronal cells from hydrogen peroxide-induced oxidative stress. Food and Chemical Toxicology, 2015, 80, 41-51.	3.6	46
79	Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites. Archives of Pharmacal Research, 2015, 38, 2083-2091.	6.3	42
80	<i>Lonicera japonica</i> THUNB. Extract Inhibits Lipopolysaccharide-Stimulated Inflammatory Responses by Suppressing NF- <i>κ</i> B Signaling in BV-2 Microglial Cells. Journal of Medicinal Food, 2015, 18, 762-775.	1.5	23
81	Direct C–H alkylation and indole formation of anilines with diazo compounds under rhodium catalysis. Chemical Communications, 2015, 51, 17229-17232.	4.1	106
82	Strain Differences in the Chronic Mild Stress Animal Model of Depression and Anxiety in Mice. Biomolecules and Therapeutics, 2014, 22, 453-459.	2.4	48
83	Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. Pharmacogenetics and Genomics, 2014, 24, 113-117.	1.5	20
84	Eucommia ulmoides Oliv. bark. attenuates 6-hydroxydopamine-induced neuronal cell death through inhibition of oxidative stress in SH-SY5Y cells. Journal of Ethnopharmacology, 2014, 152, 173-182.	4.1	41
85	Sulfuretin inhibits 6-hydroxydopamine-induced neuronal cell death via reactive oxygen species-dependent mechanisms in human neuroblastoma SH-SY5Y cells. Neurochemistry International, 2014, 74, 53-64.	3.8	29
86	Transient Receptor Potential Vanilloid Type 1 Channel May Modulate Opioid Reward. Neuropsychopharmacology, 2014, 39, 2414-2422.	5.4	38
87	Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 971, 58-63.	2.3	13
88	Effects of CYP2C19 Genetic Polymorphisms on Atomoxetine Pharmacokinetics. Journal of Clinical Psychopharmacology, 2014, 34, 139-142.	1.4	29
89	Inhibitory Effects of Eucommia ulmoides Oliv. Bark on Scopolamine-Induced Learning and Memory Deficits in Mice. Biomolecules and Therapeutics, 2013, 21, 462-469.	2.4	45
90	Determination of 19 Preservatives in Various Matrices by High-Performance Liquid Chromatography. Analytical Letters, 2012, 45, 2148-2160.	1.8	13

#	Article	IF	CITATIONS
91	Tamsulosin Exposure Is Significantly Increased by the <i>CYP2D6*10/*10</i> Genotype. Journal of Clinical Pharmacology, 2012, 52, 1934-1938.	2.0	20
92	Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 885-886, 103-108.	2.3	12
93	Determination of tamsulosin in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 909, 65-69.	2.3	14
94	ANALYTICAL LC-MS/MS METHOD FOR EZETIMIBE AND ITS APPLICATION FOR PHARMACOKINETIC STUDY. Journal of Liquid Chromatography and Related Technologies, 2012, 35, 141-152.	1.0	9
95	CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. European Journal of Clinical Pharmacology, 2012, 68, 149-154.	1.9	27
96	Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. International Journal of Clinical Pharmacology and Therapeutics, 2012, 50, 683-689.	0.6	24
97	Effects of <i>CYP2C9</i> * <i>1/</i> * <i>13</i> on the pharmacokinetics and pharmacodynamics of meloxicam. British Journal of Clinical Pharmacology, 2011, 71, 550-555.	2.4	45
98	Effects of the CYP2C9*1/*13 Genotype on the Pharmacokinetics of Lornoxicam. Basic and Clinical Pharmacology and Toxicology, 2011, 109, 476-480.	2.5	22
99	Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacologica Sinica, 2011, 32, 1303-1308.	6.1	38
100	Determination of Iron, Copper, Zinc, Lead, Nickel and Cadmium in Cosmetic Matrices by Flame Atomic Absorption Spectroscopy. Analytical Letters, 2010, 43, 259-268.	1.8	26
101	Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Archives of Pharmacal Research, 2009, 32, 269-273.	6.3	19
102	HPLC Analysis of Plasma Glipizide and its Application to Pharmacokinetic Study. Journal of Liquid Chromatography and Related Technologies, 2009, 32, 1969-1977.	1.0	5
103	Analytical HPLC Method Validation of Amiloride and Its Pharmacokinetic Study in Humans. Journal of Liquid Chromatography and Related Technologies, 2008, 31, 2455-2466.	1.0	5
104	Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 859, 69-73.	2.3	71
105	Allele and genotype frequencies of CYP2C9 in a Korean population. British Journal of Clinical Pharmacology, 2005, 60, 418-422.	2.4	82
106	Increases in [³ H]-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor binding and mRNA expression of AMPA-sensitive glutamate receptor A (GluR-A) subunits in rats withdrawn from butorphanol. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2005, 68, 2163-2174.	2.3	0
107	Effects ofCoptis japonica on morphine-induced conditioned place preference in mice. Archives of Pharmacal Research, 2003, 26, 540-544.	6.3	15
108	Effects of heme oxygenase system on the cyclooxygenase in the primary cultured hypothalamic cells. Archives of Pharmacal Research, 2001, 24, 607-612.	6.3	6

#	Article	IF	CITATIONS
109	NMDA-type glutamatergic modulation in dopaminergic activation measured by apomorphine-Induced cage climbing behaviors. Archives of Pharmacal Research, 2001, 24, 613-617.	6.3	1